Recent Updates
Recently added Catalysts

MYO-029

Phase 1

Healthy | Small molecule | Other |Pfizer, Inc.|Last Updated: Nov 26, 2007

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment72
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00563810Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029PHASE1 COMPLETED 72Oct 1, 2004Apr 1, 2006Nov 26, 2007 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
To assess safety and tolerability.
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelSINGLE_GROUP
PurposeHEALTH_SERVICES_RESEARCH
Interventions
NameTypeDescription
MYO-029DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 80 Years
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Men aged 18 to 45 years inclusive on study day 1. * Elderly men and women aged 65 to 80 years inclusive on study day 1. * Women must be postmenopausal for \> or = 1 year (with estradiol \< 25 pg/mL and an FSH \> 40 mIU/mL). * Healthy as determined by the investigator on the ba...

Unlock Eligibility Criteria